Other languages Cybin Inc.

Equities

CYBN

CA23256X1006

Real-time Estimate Cboe BZX Other stock markets 07:33:40 18/06/2024 pm IST			5-day change	1st Jan Change
0.275 ^USD	+1.18%		-9.83%	-33.29%

11/06	Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	CI
06/05	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	11/06
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	06/05
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15/03
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3	15/03
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3	15/03
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	14/03
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur	14/03
Annonce d’un placement privé sursouscrit de 150 millions USD	14/03
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt	13/03
Sector Update: Health Care Stocks Ease Wednesday Afternoon	13/03
Ankündigung einer überzeichneten Privatplatzierung von 150 Millionen US-Dollar	13/03
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump	13/03
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	13/03
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	23/01
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	23/01
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	08/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cybin Inc.

Equities

CYBN

CA23256X1006

Other languages

Filters